



This is a repository copy of *Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/100048/>

Version: Supplemental Material

Article:

O'Brien, M.E.R., Gaafar, R., Hasan, B. et al. (12 more authors) (2015) Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). *European Journal of Cancer*, 51 (12). pp. 1511-1528. ISSN 0959-8049

<https://doi.org/10.1016/j.ejca.2015.04.026>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>


Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Figure 1: Study design and patient flow



ITT: Intention-to treat

Figure 2: Treatment duration (weeks)

Treatment duration (weeks)				Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Weeks)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)	
Placebo	50	50	14.07 (6.43, 14.86)	2.0 (0.2, 9.2)	1.00	0.040	
Pazopanib	50	45	14.43 (8.86, 25.00)	12.0 (4.3, 24.0)	0.65 (0.43, 0.98)	Log-rank test: p-value=0.038	

Treatment duration (weeks)




Figure 4: Progression Free Survival (PFS)

Parameter	Levels	Parameter Estimate (Standard Error)	Hazard Ratio (95% CI)	P-value
Treatment arm	Placebo		1.00	0.068 (df=1)
	Pazopanib	-0.404 (0.2211)	0.67 (0.43, 1.03)	
Histology	Squamous		1.00	0.184 (df=1)
	Non-Squamous	-0.351 (0.2641)	0.70 (0.42, 1.18)	
Response to Induction Chemo	CR/PR		1.00	0.496 (df=1)
	SD	-0.168 (0.2463)	0.85 (0.52, 1.37)	

Progression free survival




Table 1: Patient Demography

	Treatment arm	
	Placebo (N=52)	Pazopanib (N=50)
	N (%)	N (%)
Histology		
Squamous	11 (21.2)	9 (18.0)
non-squamous	41 (78.8)	41 (82.0)
Performance status		
0	11 (21.2)	18 (36.0)
1	39 (75.0)	32 (64.0)
2	2 (3.8)	0 (0.0)
Response after the last cycle of induction therapy		
Partial response	14 (26.9)	16 (32.0)
Stable disease	38 (73.1)	34 (68.0)
Age category		
26-55 years	8 (15.3)	15 (30.0)
56-65 years	19 (36.5)	12 (24.0)
66-75 years	19 (36.5)	17 (34.0)
>75 years	6 (11.5)	6 (12.0)
Median	64.6	64.2
Range	25.9 - 80.7	28.4 - 81.1
Sex		
Male	25 (48.1)	21 (42.0)
Female	27 (51.9)	29 (58.0)
Tobacco use		
Never	10 (19.2)	11 (22.0)
Past	35 (67.3)	26 (52.0)
Current	4 (7.7)	11 (22.0)
Missing	3 (5.8)	2 (4.0)
Number of years smoking		
Median	30.0	30.0
Range	0.0 - 68.0	0.0 - 59.0

Table 2 - Induction chemo

	Treatment arm	
	Placebo (N=52)	Pazopanib (N=50)
	N (%)	N (%)
Number of induction chemotherapy cycles received		
4	48 (92.3)	49 (98.0)
6	4 (7.7)	1 (2.0)
Category of induction chemo		
Cisplatin/ Pemetrexed	17 (32.6)	15 (30.0)
Carboplatin/Gemcitabine	10 (19.2)	10 (20.0)
Carboplatin/ Vinorelbine	2 (3.8)	3 (6.0)
Carboplatin/Pemetrexed	14 (26.9)	11 (22.0)
Cisplatin/Gemcitabine	5 (9.6)	4 (8.0)
Oral Vinorelbine	0 (0.0)	1 (2.0)
Cisplatin/Vinorelbine	2 (3.8)	2 (4.0)
Cisplatin/Carboplatin/Gemcitabine	1 (1.9)	0 (0.0)
/ Bortezomib		
Cisplatin /Docetaxel	0 (0.0)	3 (6.0)
Carboplatin/Paclitaxel	0 (0.0)	1 (2.0)
Paclitaxel/ Pemetrexed	1 (1.9)	0 (0.0)

Table 3: Relative Dose intensities and discontinuations

	Treatment arm	
	Placebo (N=50) N (%)	Pazopanib (N=50) N (%)
Relative dose intensity(%) for the first 2 weeks		
90-110%	49 (98.0)	48 (96.0)
>110%	1 (2.0)	2 (4.0)
Relative dose intensity(%) after the first 2 weeks		
<=50%	1 (2.0)	2 (4.0)
50-70%	0 (0.0)	4 (8.0)
70-90%	2 (4.0)	17 (34.0)
90-110%	44 (88.0)	25 (50.0)
Patients did not continue after the 1st 2 weeks	3 (6.0)	2 (4.0)
Major reason for protocol discontinuation		
PD	42 (84.0)	30 (66.7)
adverse event	1 (2.0)	10 (22.2)
investigator's decision	6 (12.0)	2 (4.4)
patient's decision	0 (0.0)	2 (4.4)
other	1 (2.0)	1 (2.2)

Table 4: Toxicity/Adverse Events(CTCAE V. 4.0)

	Treatment arm	
	Placebo (N=50)	Pazopanib (N=50)
Grade reported	N (%)	N (%)
Myocardial infarction		
2	0 (0.0)	1 (2.0)
3	0 (0.0)	1 (2.0)
Abdominal pain		
1	3 (6.0)	8 (16.0)
2	3 (6.0)	2 (4.0)
3	0 (0.0)	1 (2.0)
Diarrhea		
1	3 (6.0)	14 (28.0)
2	2 (4.0)	9 (18.0)
3	1 (2.0)	1 (2.0)
Nausea		
1	8 (16.0)	13 (26.0)
2	5 (10.0)	6 (12.0)
3	0 (0.0)	1 (2.0)
Vomiting		
1	6 (12.0)	7 (14.0)
2	1 (2.0)	5 (10.0)
3	2 (4.0)	0 (0.0)
Fatigue		
1	13 (26.0)	13 (26.0)
2	10 (20.0)	16 (32.0)
3	1 (2.0)	4 (8.0)
Anorexia		
1	6 (12.0)	11 (22.0)
2	5 (10.0)	6 (12.0)
3	1 (2.0)	3 (6.0)
Dizziness		
1	3 (6.0)	5 (10.0)
3	0 (0.0)	1 (2.0)
Peripheral motor neuropathy		
2	2 (4.0)	0 (0.0)
Peripheral sensory neuropathy		
1	7 (14.0)	10 (20.0)
2	2 (4.0)	3 (6.0)
Rash maculo-papular		
1	8 (16.0)	5 (10.0)
2	0 (0.0)	1 (2.0)
3	0 (0.0)	1 (2.0)

Hypertension		
1	6 (12.0)	2 (4.0)
2	20 (40.0)	19 (38.0)
3	4 (8.0)	19 (38.0)
Thromboembolic event		
1	2 (4.0)	4 (8.0)
2	2 (4.0)	2 (4.0)
3	0 (0.0)	1 (2.0)
Other toxicity		
1	16 (32.0)	9 (18.0)
2	18 (36.0)	19 (38.0)
3	4 (8.0)	11 (22.0)
5	1 (2.0)	1 (2.0)

Table 5: Further antitumor therapy after the end of treatment

	Treatment arm	
	Placebo (N=50) N (%)	Pazopanib (N=45) N (%)
Chemotherapy		
no	33 (66.0)	32 (71.1)
yes	17 (34.0)	13 (28.9)
Radiotherapy		
no	41 (82.0)	36 (80.0)
yes	9 (18.0)	9 (20.0)
Surgery		
no	50 (100.0)	45 (100.0)
Hormonotherapy		
no	50 (100.0)	45 (100.0)
Targeted agents		
no	34 (68.0)	37 (82.2)
yes	16 (32.0)	8 (17.8)
Other		
no	49 (98.0)	44 (97.8)
yes	1 (2.0)	1 (2.2)

APPENDIX

OS: Sub-group analysis according to stratification and other important factors

OS: Analysis Based on Histology

Figure 5: OS for Squamous

Overall survival						
Treatment arm	Patients (N)	Observed Events (O)	Non-parametric		Cox model	
			Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	11	4	20.70 (1.81, 20.70)	81.8 (44.7, 95.1)	1.00	0.332
Pazopanib	9	6	8.90 (5.42, 17.41)	44.4 (13.6, 71.9)	1.98 (0.49, 8.05)	
					Log-rank test:	p-value=0.332





Figure 6: OS for Non-Squamous

Overall survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	41	23	11.79 (9.76, 15.05)	45.8 (27.6, 62.3)	1.00	0.115
Pazopanib	41	14	Not reached	60.5 (42.3, 74.6)	0.59 (0.30, 1.15)	
					Log-rank test:	p-value=0.115

**Overall survival
Non-Squamous**



OS: Analysis Based on Response at Induction Chemo

Figure 7: OS for CR/PR

Overall survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	14	7	11.89 (8.44, 14.72)	48.4 (14.1, 76.4)	1.00	0.407
Pazopanib	16	5	Not reached	61.9 (30.8, 82.3)	0.61 (0.19, 1.97)	
					Log-rank test:	p-value=0.407

Overall survival CR/PR





Figure 8: OS for SD

Overall survival				Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)	
Placebo	38	20	12.42 (9.79, 19.29)	51.6 (32.2, 68.0)	1.00	0.476	
Pazopanib	34	15	17.41 (8.90, N)	55.3 (36.3, 70.8)	0.78 (0.40, 1.53)	Log-rank test: p-value=0.475	

**Overall survival
SD**



OS: Analysis Based on Gender

Figure 9: OS for Male

Overall survival			Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	25	12	12.29 (5.72, N)	58.6 (34.6, 76.4)	1.00	0.072
Pazopanib	21	6	Not reached	70.6 (43.2, 86.6)	0.41 (0.15, 1.11)	
					Log-rank test:	p-value=0.071





Figure 10: OS for Female

Overall survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	27	15	11.89 (10.28, 19.29)	48.3 (25.8, 67.6)	1.00	0.922
Pazopanib	29	14	10.45 (6.80, N)	47.0 (26.9, 64.7)	1.04 (0.50, 2.15)	
					Log-rank test:	p-value=0.922

**Overall survival
Female**



OS: Analysis based on Smoking Status

Figure 11: OS for Current Smoker

Overall survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	4	2	10.28 (0.33, N)	37.5 (1.1, 80.8)	1.00	0.265
Pazopanib	11	4	17.41 (7.72, 17.41)	66.7 (27.2, 88.2)	0.37 (0.06, 2.27)	
					Log-rank test:	p-value=0.265





Figure 11: OS for Former and Non-Smoker

Overall survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	48	25	12.29 (9.79, 16.59)	52.2 (34.3, 67.3)	1.00	0.364
Pazopanib	39	16	Not reached	54.4 (36.4, 69.2)	0.75 (0.40, 1.40)	
					Log-rank test:	p-value=0.363

**Overall survival
Former Smoker**



PFS: Sub-group analysis according to stratification and other important factors

PFS: Analysis Based on Histology

Figure 12: PFS for Squamous

Progression free survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	11	10	3.06 (0.76, 7.03)	36.4 (11.2, 62.7)	1.00	0.069
Pazopanib	9	9	3.29 (1.38, 8.71)	44.4 (13.6, 71.9)	0.38 (0.13, 1.12)	
					Log-rank test:	p-value=0.067

**Progression free survival
Squamous**





Figure 13: PFS for Squamous

Progression free survival			Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	41	35	3.22 (2.07, 5.09)	42.5 (27.2, 57.0)	1.00	0.147
Pazopanib	41	31	4.83 (2.79, 5.88)	57.8 (41.1, 71.3)	0.70 (0.43, 1.14)	
					Log-rank test:	p-value=0.143

**Progression free survival
Non-Squamous**



PFS: Analysis Based on Response at Induction Chemo

Figure 14: PFS for patients with CR/PR at induction

Progression free survival						
Treatment arm	Patients (N)	Observed Events (O)	Non-parametric		Cox model	
			Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	14	12	3.22 (1.35, 7.10)	38.5 (14.1, 62.8)	1.00	0.334
Pazopanib	16	11	4.21 (1.28, 12.65)	54.6 (27.4, 75.3)	0.66 (0.29, 1.54)	
					Log-rank test:	p-value=0.332

**Progression free survival
CR/PR**





Figure 15: PFS for patients with SD at induction

Progression free survival			Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 1 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	38	33	3.22 (1.74, 5.13)	8.6 (1.8, 22.3)	1.00	0.137
Pazopanib	34	29	4.88 (2.79, 7.66)	9.1 (1.8, 23.9)	0.68 (0.41, 1.13)	
Log-rank test:					p-value=0.134	

**Progression free survival
SD**



PFS: Analysis Based on Gender

Figure 16: PFS for Male

Progression free survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	25	23	3.22 (1.71, 5.09)	40.0 (21.3, 58.1)	1.00	0.005
Pazopanib	21	16	5.32 (3.29, 8.71)	70.6 (45.8, 85.6)	0.36 (0.18, 0.76)	
					Log-rank test:	p-value=0.004





Figure 17: PFS for Female

Progression free survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	27	22	3.15 (1.45, 5.49)	42.3 (23.5, 60.0)	1.00	0.669
Pazopanib	29	24	3.22 (1.81, 5.88)	44.8 (26.5, 61.6)	0.88 (0.49, 1.58)	
Log-rank test:					p-value=0.667	

**Progression free survival
Female**



PFS: Analysis based on Smoking Status

Figure 18: PFS for Current Smokers

Progression free survival		Non-parametric		Cox model		
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	4	4	3.24 (0.33, 3.32)	0.0 (,)	1.00	0.178
Pazopanib	11	8	5.88 (1.38, N)	54.6 (22.9, 78.0)	0.41 (0.11, 1.56)	
					Log-rank test:	p-value=0.178




Figure 19: PFS for Former and Non-Smoker

Progression free survival			Non-parametric		Cox model	
Treatment arm	Patients (N)	Observed Events (O)	Median (95% CI) (Months)	% at 0.3 Year(s) (95% CI)	Hazard Ratio (95% CI)	P-Value (Score test)
Placebo	48	41	3.22 (1.74, 5.13)	44.7 (30.3, 58.1)	1.00	0.196
Pazopanib	39	32	4.30 (2.79, 5.32)	55.5 (38.5, 69.5)	0.74 (0.46, 1.17)	
Log-rank test:						p-value=0.192

Progression free survival

